SRNE / Sorrento Therapeutics, Inc. - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 (November 3, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of in

MANUFACTURING TECHNOLOGY TRANSFER AGREEMENT

Exhibit 10.1 MANUFACTURING TECHNOLOGY TRANSFER AGREEMENT This MANUFACTURING TECHNOLOGY TRANSFER AGREEMENT (this “Agreement”) is made and entered into as of November 2, 2023 (the “Effective Date”) by and among SORRENTO THERAPEUTICS, INC., a Delaware corporation (“Seller”) and YUHAN CORPORATION, a Korean corporation (“Buyer”). Each of Seller and Buyer are referred to herein as a “Party” and together

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2023 (October 30, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2023 (October 30, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of in

ASSET PURCHASE AGREEMENT BY AND BETWEEN SORRENTO THERAPEUTICS, INC., YUHAN CORPORATION DATED AS OF OCTOBER 30, 2023

Exhibit 2.1 Execution Version ASSET PURCHASE AGREEMENT BY AND BETWEEN SORRENTO THERAPEUTICS, INC., AND YUHAN CORPORATION DATED AS OF OCTOBER 30, 2023 THIS ASSET PURCHASE AGREEMENT IS SUBJECT TO REVISION BY SELLER AT ANY TIME AND MUST BE KEPT CONFIDENTIAL IN ACCORDANCE WITH THE TERMS OF THE CONFIDENTIALITY AGREEMENT ENTERED INTO BETWEEN THE RECIPIENT OF THIS AGREEMENT AND SELLER. THIS DOCUMENT HAS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2023 SORRENTO THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2023 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commi

From: Tammy Reilly <[…***…]@[…***…].com>

Exhibit 17.1 From: Tammy Reilly <[…***…]@[…***…].com> Sent: Wednesday, October 25, 2023 11:46 AM To: Henry Ji <[…***…]@sorrentotherapeutics.com> Subject: BOD Resignation Good morning, It is with dismay that I inform you of my decision to resign from the Board of Directors for Sorrento Therapeutics effective immediately. I have become increasingly concerned at the CRO’s continued lack of communicat

CELU / Celularity Inc - Class A / Sorrento Therapeutics, Inc. - SC 13G/A Passive Investment

Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* CELULARITY INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 151190105

STOCK PURCHASE AGREEMENT

Exhibit 2.1 STOCK PURCHASE AGREEMENT September 29, 2023 Sorrento Therapeutics, Inc. 455 Directors Place San Diego, California 92121 To Whom it May Concern: Sorrento Therapeutics, Inc., a Delaware corporation (the “Seller”), hereby agrees with Dr. Robert J. Hariri, M.D., Ph. D, an individual (the “Purchaser” and, together with the Seller, the “Parties”) as follows: 1. PURCHASE PRICE. Pursuant to Se

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 5, 2023 (September 29, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 5, 2023 (September 29, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of i

STOCK PURCHASE AGREEMENT BY AND BETWEEN SCILEX HOLDING COMPANY SORRENTO THERAPEUTICS, INC. September 21, 2023 STOCK PURCHASE AGREEMENT

Exhibit 2.1 STOCK PURCHASE AGREEMENT BY AND BETWEEN SCILEX HOLDING COMPANY AND SORRENTO THERAPEUTICS, INC. September 21, 2023 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT is made and entered into as of September 21, 2023 (this “Agreement”), by and between Scilex Holding Company, a Delaware corporation (the “Purchaser”) and Sorrento Therapeutics, Inc., a Delaware corporation (the “Seller”

US80880W1062 / SCILEX HOLDING CO / Sorrento Therapeutics, Inc. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Scilex Holding Company (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securiti

ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT

Exhibit 10.1 ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT THIS ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT (this “Agreement”) is executed on September 21, 2023 (the “Effective Date”), by and among Scilex Holding Company (“Scilex”), Oramed Pharmaceuticals Inc. (“Oramed”), Sorrento Therapeutics, Inc. (“Sorrento”), and Scintilla Pharmaceuticals, Inc. (together with Sorrento, the “Debtors”). W I T N

Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company

Exhibit 99.2 Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company SAN DIEGO, CA. September 22, 2023 /Newswire/ - Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento” or “Company”), a biopharmaceutical company dedicated to the development of life-sa

STOCK PURCHASE AGREEMENT BY AND BETWEEN SCILEX HOLDING COMPANY SORRENTO THERAPEUTICS, INC. September 21, 2023 STOCK PURCHASE AGREEMENT

Exhibit 13 STOCK PURCHASE AGREEMENT BY AND BETWEEN SCILEX HOLDING COMPANY AND SORRENTO THERAPEUTICS, INC.

MUTUAL TERMINATION AND RELEASE AGREEMENT

Exhibit 14 MUTUAL TERMINATION AND RELEASE AGREEMENT This Mutual Termination and Release Agreement (this “Agreement”) is entered into as of September 21, 2023, by and between Sorrento Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 26, 2023 (September 20,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 26, 2023 (September 20, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction o

ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT

Exhibit 15 ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT THIS ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT (this “Agreement”) is executed on September 21, 2023 (the “Effective Date”), by and among Scilex Holding Company (“Scilex”), Oramed Pharmaceuticals Inc.

MUTUAL TERMINATION AND RELEASE AGREEMENT

Exhibit 2.2 MUTUAL TERMINATION AND RELEASE AGREEMENT This Mutual Termination and Release Agreement (this “Agreement”) is entered into as of September 21, 2023, by and between Sorrento Therapeutics, Inc., a Delaware corporation, (“Sorrento”), and Oramed Pharmaceuticals, Inc., a Delaware corporation (“Oramed”, and together with Sorrento, the “Parties”). WHEREAS, on February 13, 2023, Sorrento, toget

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

EXHIBIT 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On September 21, 2023, Sorrento Therapeutics, Inc. (the “Company” or “Sorrento”) entered into a stock purchase agreement with Scilex Holding Company (“Scilex”) whereby Scilex acquired (i) all of the shares of Scilex common stock owned by Sorrento (other than 1,917,210 shares of Scilex common stock held in abeyance by Sor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2023 (September 11,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2023 (September 11, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction o

NON-BINDING TERM SHEET September 11, 2023

Exhibit 99.1 Execution Version NON-BINDING TERM SHEET September 11, 2023 The following non-binding term sheet (“Term Sheet”) outlines, in addition to the other matters described herein, the proposed terms of (A) the declaration of Scilex as the winning bidder for the purchase of the Securities Transfer (as defined below) pursuant to the Winning Bid (as defined below), and either (B) the closing of

TERM SHEET FOR SENIOR SECURED NOTE AND WARRANTS AND RELATED MATTERS September 11, 2023

Exhibit 99.2 EXECUTION TERM SHEET FOR SENIOR SECURED NOTE AND WARRANTS AND RELATED MATTERS September 11, 2023 PARTIES Company: Scilex Holding Company, a Delaware corporation (the “Company” or “SCLX”). Investor: Oramed Pharmaceuticals, Inc. (the “Investor” or “Oramed”). Sorrento: Sorrento Therapeutics Inc., a Delaware corporation (“Sorrento”). NON-BINDING TERMS Securities: In exchange for the consu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2023 (August 21, 2023)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2023 (August 21, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of inco

SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT

Exhibit 2.3 Execution Version SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT THIS SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT (this “Amendment”) is made as of August 21, 2023, by and between Sorrento Therapeutics, Inc., a Delaware corporation (the “Seller”), and Oramed Pharmaceuticals Inc., a Delaware corporation (the “Purchaser”). Capitalized terms used herein without definition shall have the mea

UST Form 11-MOR (12/01/2021) 2 Debtor's Name SCINTILLA PHARMACEUTICALS, INC. Case No. 23-90084 Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $60,000 b. Total receipts (net of transfers between acc

Exhibit 99.2 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SCINTILLA PHARMACEUTICALS, INC. Debtor(s) § § § § Case No. 23-90084 Lead Case No. 23-90085 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 06/30/2023 Petition Date: 02/13/2023 Months Pending: 5 Industry Classification: 3 2 5 4 Reporting Meth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 21, 2023 (August 15, 2023)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 21, 2023 (August 15, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of inco

UST Form 11-MOR (12/01/2021) 2 Debtor's Name SORRENTO THERAPEUTICS, INC. Case No. 23-90085 Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $35,876,091 b. Total receipts (net of transfers between acc

Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SORRENTO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 23-90085 Lead Case No. 23-90085 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 06/30/2023 Petition Date: 02/13/2023 Months Pending: 5 Industry Classification: 3 2 5 4 Reporting Method:

US80880W1062 / SCILEX HOLDING CO / Sorrento Therapeutics, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Scilex Holding Company (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36150 SORRENTO THERAPEUTICS,

Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid

Exhibit 99.2 FOR IMMEDIATE RELEASE August 8, 2023 Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid SAN DIEGO, August 8, 2023 – Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or “the Debtor”), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and

Stalking Horse Stock Purchase Term Sheet

Exhibit 99.1 Execution Version Stalking Horse Stock Purchase Term Sheet This term sheet (this “Stalking Horse Term Sheet”) sets forth the principal terms of a proposed equity sale transaction (the “Sale”) between the parties described herein. Consummation of the Sale is subject to (i) final definitive documentation to be negotiated in good faith between the parties, (ii) the satisfaction or waiver

Amendment Agreement to Stock Purchase Agreement, Dated August 9, 2023, between Sorrento Therapeutics, Inc. amd Oramed Pharmaceutircals Inc.

Exhibit 2.2 FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT THIS FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT (this “Amendment”) is made as of August 9, 2023, by and between Sorrento Therapeutics, Inc., a Delaware corporation (the “Seller”), and Oramed Pharmaceuticals Inc., a Delaware corporation (the “Purchaser”). Capitalized terms used herein without definition shall have the meaning ascribed to such

Senior Secured, Super-Priority Debtor-In-Possession Loan and Security Agreement, dated March 30, 2023, by and among Sorrento Therapeutics, Inc., Scintilla Pharmaceuticals, Inc., and JMB Capital Partners Lending, LLC.

Exhibit 10.1 Execution Version SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION LOAN AND SECURITY AGREEMENT by and among SORRENTO THERAPEUTICS, INC. SCINTILLA PHARMACEUTICALS, INC. as Borrowers, and Oramed Pharmaceuticals Inc., as Lender Dated as of August 9, 2023 TABLE OF CONTENTS Page 1. DEFINITIONS AND CONSTRUCTION. 2 1.1 Definitions 2 1.2 Accounting Terms 14 1.3 UCC 14 1.4 Construction 14 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 (August 4, 2023)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 (August 4, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incor

Stock Purchase Agreement, Dated August 7, 2023 between Sorrento Therapeutics, Inc. and Oramed Pharmaceuticals Inc.

Exhibit 2.1 Execution Version CONFIDENTIAL STOCK PURCHASE AGREEMENT BETWEEN ORAMED PHARMACEUTICALS INC. AND SORRENTO THERAPEUTICS, INC. August 7, 2023 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT is made and entered into as of August 7, 2023 (this “Agreement”), between Oramed Pharmaceuticals Inc., a Delaware corporation (“Purchaser”), on the one hand, and Sorrento Therapeutics, Inc., a D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-36150 CUSIP Number: 83587F202 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☑ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Trans

Project Stallion Business Plan Overview July 11, 2023

Exhibit 99.1 Project Stallion Business Plan Overview July 11, 2023 Disclaimer 2 This presentation contains selected information pertaining to the business and operations of Sorrento Therapeutics, Inc. (“ Sorrento ” or the “ Company ”). The purpose of this presentation is to assist interested parties in evaluating (i) a potential sale of all or a portion of the Company’s assets, (ii) a potential de

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2023 (August 1, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorp

As filed with the Securities and Exchange Commission on July 18, 2023

As filed with the Securities and Exchange Commission on July 18, 2023 Registration No.

UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SORRENTO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 23-90085 Lead Case No. 23-90085 Jointly Administered Monthly Operating Report Chap

Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SORRENTO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 23-90085 Lead Case No. 23-90085 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2023 Petition Date: 02/13/2023 Months Pending: 4 Industry Classification: 3254 Reporting Method: Acc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2023 (July 3, 2023) SORR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2023 (July 3, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorpora

UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SCINTILLA PHARMACEUTICALS, INC. Debtor(s) § § § § Case No. 23-90084 Lead Case No. 23-90085 Jointly Administered Monthly Operating Report

Exhibit 99.2 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SCINTILLA PHARMACEUTICALS, INC. Debtor(s) § § § § Case No. 23-90084 Lead Case No. 23-90085 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2023 Petition Date: 02/13/2023 Months Pending: 4 Industry Classification: 3254 Reporting Method:

Debtor-in-Possession Term Loan Facility Summary of Terms and Conditions, dated as of July 5, 2023, between Sorrento Therapeutics, Inc., Scintilla Pharmaceuticals, Inc. and Scilex Holding Company.

Exhibit 10.1 July 5, 2023 SORRENTO THERAPEUTICS, INC. SCINTILLA PHARMACEUTICALS, INC. Debtor-in-Possession Term Loan Facility Summary of Terms and Conditions This term sheet (together with the exhibits and schedules hereto, the “Term Sheet”) sets forth a summary of the terms and conditions with respect to the DIP Facility (as defined below) from and after, and subject to, the entry of the Junior I

Intercreditor and Subordination Agreement, dated as of July 5, 2023, by and among JMB Capital Partners Lending, LLC and Scilex Holding Company.

Exhibit 10.2 Execution Version INTERCREDITOR AND SUBORDINATION AGREEMENT This Agreement (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) is entered into as of July 5, 2023 by and among JMB CAPITAL PARTNERS LENDING, LLC, a California limited liability company (in its capacity as the lender under the Senior DIP Agreement referred to below, the “Senior Le

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2023 (July 5, 2023) SORRE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2023 (July 5, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorporat

As filed with the Securities and Exchange Commission on June 21, 2023

As filed with the Securities and Exchange Commission on June 21, 2023 Registration No.

Calculation of Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Sorrento Therapeutics, Inc.

UST Form 11-MOR (12/01/2021) 2 Debtor's Name SORRENTO THERAPEUTICS, INC. Case No. 23-90085 Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $25,667,956 b. Total receipts (net of transfers between acc

Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SORRENTO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 23-90085 Lead Case No. 23-90085 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 04/30/2023 Petition Date: 02/13/2023 Months Pending: 3 Industry Classification: 3 2 5 4 Reporting Method:

UST Form 11-MOR (12/01/2021) 2 Debtor's Name SCINTILLA PHARMACEUTICALS, INC. Case No. 23-90084 Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $60,000 b. Total receipts (net of transfers between acc

Exhibit 99.2 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SCINTILLA PHARMACEUTICALS, INC. Debtor(s) § § § § Case No. 23-90084 Lead Case No. 23-90085 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 04/30/2023 Petition Date: 02/13/2023 Months Pending: 3 Industry Classification: 3 2 5 4 Reporting Meth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2023 (June 14, 2023) SOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2023 (June 14, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorpor

June 15, 2023

Exhibit 99.1 FOR IMMEDIATE RELEASE June 15, 2023 SAN DIEGO, June 15, 2023 – Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2023 (June 14, 2023) SOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2023 (June 14, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorpor

UST Form 11-MOR (12/01/2021) 2 Debtor's Name SORRENTO THERAPEUTICS, INC. Case No. 23-90085 Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $31,359,015 b. Total receipts (net of transfers between acc

Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SORRENTO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 23-90085 Lead Case No. 23-90085 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 03/31/2023 Petition Date: 02/13/2023 Months Pending: 2 Industry Classification: 3 2 5 4 Reporting Method:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2023 (May 17, 2023) SORRE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2023 (May 17, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorporat

UST Form 11-MOR (12/01/2021) 2 Debtor's Name SCINTILLA PHARMACEUTICALS, INC. Case No. 23-90084 Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $60,000 b. Total receipts (net of transfers between acc

Exhibit 99.2 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SCINTILLA PHARMACEUTICALS, INC. Debtor(s) § § § § Case No. 23-90084 Lead Case No. 23-90085 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 03/31/2023 Petition Date: 02/13/2023 Months Pending: 2 Industry Classification: 3 2 5 4 Reporting Meth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36150 SORRENTO THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 (May 12, 2023) SORRE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 (May 12, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorporat

Sorrento Therapeutics, Inc.’s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers’ Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accou

Exhibit 99.1 FOR IMMEDIATE RELEASE May 14, 2023 Sorrento Therapeutics, Inc.’s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers’ Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accounts SAN DIEGO, May 14, 2023 – Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutica

Power of Attorney is contained on the signature page of the Post-Effective Amendment No. 1 to Form S-3.

As filed with the Securities and Exchange Commission on May 12, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-36150 CUSIP Number: 83587F202 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☑ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2023 (May 1, 2023) SORRENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2023 (May 1, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorporatio

Case 23 - 90085 Document 560 Filed in TXSB on 05/01/23 Page 1 of 12 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SORRENTO THERAPEUTICS, INC. Debtor(s) † † † † Case No. 23 - 90085 Lead Case No. 23 - 90085 Jointly A

Exhibit 99.1 Case 23 - 90085 Document 560 Filed in TXSB on 05/01/23 Page 1 of 12 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SORRENTO THERAPEUTICS, INC. Debtor(s) † † † † Case No. 23 - 90085 Lead Case No. 23 - 90085 Jointly Administered Monthly Operating Report Chapter 11 Petition Date: 02/13/2023 Reporting Period Ended: 02/28/2023 Months Pending: 1 Reporting

Case 23 - 90085 Document 561 Filed in TXSB on 05/01/23 Page 1 of 12 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SCINTILLA PHARMACEUTICALS, INC. Debtor(s) † † † † Case No. 23 - 90084 Lead Case No. 23 - 90085 Joint

Exhibit 99.2 Case 23 - 90085 Document 561 Filed in TXSB on 05/01/23 Page 1 of 12 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SCINTILLA PHARMACEUTICALS, INC. Debtor(s) † † † † Case No. 23 - 90084 Lead Case No. 23 - 90085 Jointly Administered Monthly Operating Report Chapter 11 Petition Date: 02/13/2023 Reporting Period Ended: 02/28/2023 Months Pending: 1 Report

Sorrento Therapeutics, Inc.’s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend

Exhibit 99.1 FOR IMMEDIATE RELEASE April 25, 2023 Sorrento Therapeutics, Inc.’s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend SAN DIEGO, April 25, 2023 – Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractab

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2023 (April 25, 2023) S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2023 (April 25, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 20, 2023 (April 14, 2023) S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 20, 2023 (April 14, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 20, 2023 (April 18, 2023) S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 20, 2023 (April 18, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorp

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2023 (April 7, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2023 (April 7, 2023) SO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2023 (April 7, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorpo

Senior Secured, Super-Priority Debtor-In-Possession Loan and Security Agreement, dated March 30, 2023, by and among Sorrento Therapeutics, Inc., Scintilla Pharmaceuticals, Inc., and JMB Capital Partners Lending, LLC.

Exhibit 10.1 Execution Version SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION LOAN AND SECURITY AGREEMENT by and among SORRENTO THERAPEUTICS, INC. SCINTILLA PHARMACEUTICALS, INC. as Borrowers, and JMB CAPITAL PARTNERS LENDING, LLC, as Lender Dated as of March 30, 2023 TABLE OF CONTENTS Page 1. DEFINITIONS AND CONSTRUCTION. 1 1.1 Definitions 2 1.2 Accounting Terms 13 1.3 UCC 14 1.4 Constructio

Sorrento Therapeutics, Inc. Receives Final Court Approval for $75 Million Debtor-In-Possession Financing

Exhibit 99.1 FOR IMMEDIATE RELEASE March 29, 2023 Sorrento Therapeutics, Inc. Receives Final Court Approval for $75 Million Debtor-In-Possession Financing SAN DIEGO, March 29, 2023 – Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced tha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2023 (March 29, 2023) S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2023 (March 29, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2023 ( March 16, 2023)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2023 ( March 16, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incor

Court Confirms Sorrento Therapeutics, Inc.’s $125 Million Arbitration Award Against NantPharma, LLC

Exhibit 99.1 FOR IMMEDIATE RELEASE March 17, 2023 Court Confirms Sorrento Therapeutics, Inc.’s $125 Million Arbitration Award Against NantPharma, LLC SAN DIEGO, March 17, 2023 - Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, announced that on March 16, 2023, the LA County Superior Court con

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36150 SORRENTO THERAPEUTICS, INC.

List of Subsidiaries

Exhibit 21.1 Subsidiaries of Sorrento Therapeutics, Inc. Name State or Jurisdiction of Incorporation or Organization Concortis Biosystems, Corp. Delaware Ark Animal Health, Inc. Delaware TNK Therapeutics, Inc. Delaware BioServ Corporation Delaware Adnab, Inc. Delaware ACEA Therapeutics, Inc. Cayman Islands Scilex Holding Company Delaware Semnur Pharmaceuticals, Inc. Delaware Scilex Pharmaceuticals

SRNE / Sorrento Therapeutics Inc / BlackRock Inc. Passive Investment

us83587f2020030823.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) SORRENTO THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 83587F202 - (CUSIP Number) February 28, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

US80880W1062 / SCILEX HOLDING CO / Sorrento Therapeutics, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Scilex Holding Company (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-36150 CUSIP Number: 83587F202 (Check One): ☑ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T

Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case

Exhibit 99.2 FOR IMMEDIATE RELEASE February 21, 2023 Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case SAN DIEGO, February 21, 2023 - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced tha

13 Week Cash Flow DIP Budget February 2023

Exhibit 99.3 13 Week Cash Flow DIP Budget February 2023 2 Disclaimer Cautionary Note Regarding Projections The cash flow budget, financial projections, prospective financial information or forecasts (collectively, the “Projections”) in cluded in these Cleansing Materials were not prepared with a view towards public disclosure or compliance with the published guidelines of the Securiti es and Excha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 (February 19, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 (February 19, 2023) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of

February 19, 2023 Sorrento Therapeutics, Inc. $75,000,000 Debtor-in-Possession Term Loan Facility Summary of Terms and Conditions

Exhibit 99.1 February 19, 2023 Sorrento Therapeutics, Inc. $75,000,000 Debtor-in-Possession Term Loan Facility Summary of Terms and Conditions This term sheet (together with the exhibits and schedules hereto, the “Term Sheet”) sets forth a summary of the terms and conditions with respect to the DIP Facility (as defined below) from and after, and subject to, the entry of the Interim Order (as defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 SORRENTO THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorporation) (Comm

SRNE / Sorrento Therapeutics Inc / ICS OPPORTUNITIES, LTD. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SORRENTO THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 83587F202 (CUSIP Number) FEBRUARY 15, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2023 SORRENTO THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2023 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2023 SORRENTO THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2023 SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2023 (December 2, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2023 (December 2, 2022) SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of i

SRNE / Sorrento Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Sorrento Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 83587F202 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is f

SUPPLEMENT TO FREQUENTLY ASKED QUESTIONS REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY SORRENTO THERAPEUTICS, INC.

Exhibit 99.1 sorrentotherapeutics.com 4955 Directors Place San Diego, CA 92121 SUPPLEMENT TO FREQUENTLY ASKED QUESTIONS REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY SORRENTO THERAPEUTICS, INC. This supplement is a supplement to the Frequently Asked Questions Regarding the Dividend of Scilex Holding Company Common Stock by Sorrento Therapeutics, Inc. (Sorrento) that was issued b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2023 SORRENTO THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2023 SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorporation) (Commi

SUPPLEMENT TO FREQUENTLY ASKED QUESTIONS REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY SORRENTO THERAPEUTICS, INC.

Exhibit 99.2 FOR IMMEDIATE RELEASE February 2, 2023 Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock SAN DIEGO, February 2, 2023 (GLOBE NEWSWIRE) - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a supplement to its previously issued “Frequently Asked Questions” document under the “Investors” section of its

FREQUENTLY ASKED QUESTIONS REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY SORRENTO THERAPEUTICS, INC.

Exhibit 99.1 sorrentotherapeutics.com 4955 Directors Place San Diego, CA 92121 FREQUENTLY ASKED QUESTIONS REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY SORRENTO THERAPEUTICS, INC. Q: What is the dividend of Scilex Common Stock? A: On December 30, 2022, Sorrento Therapeutics, Inc. (Sorrento) announced that its board of directors declared a stock dividend (Dividend) consisting of

FREQUENTLY ASKED QUESTIONS REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY SORRENTO THERAPEUTICS, INC.

Exhibit 99.2 FOR IMMEDIATE RELEASE January 29, 2023 Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock SAN DIEGO, January 29, 2023 (GLOBE NEWSWIRE) - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2023 SORRENTO THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2023 SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36150 33-0344842 (State or other jurisdiction of incorporation) (Commi

SCLX / Scilex Holding Company / Sorrento Therapeutics, Inc. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Scilex Holding Company (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) Common Stock - 80880W106 (CUSIP Number) Dr. Henry Ji Chairman of the Board of Directors, President and Chief Executive Officer Sorrent

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2023 SORRENTO THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2023 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2023 SORRENTO THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2023 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2022 SORRENTO THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2022 SORRENTO THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

As filed with the Securities and Exchange Commission on December 19, 2022

As filed with the Securities and Exchange Commission on December 19, 2022 Registration No.

Calculation of Filing Fee Table Form S-8 (Form Type) Sorrento Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. 2019 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on December 16, 2022).

Exhibit 10.1 SORRENTO THERAPEUTICS, INC. 2019 STOCK INCENTIVE PLAN PLAN DOCUMENT 1. Establishment, Purpose, and Types of Awards Sorrento Therapeutics, Inc. (the “Company”) hereby establishes this equity-based incentive compensation plan to be known as the “Sorrento Therapeutics, Inc. 2019 Stock Incentive Plan” (hereinafter referred to as the “Plan”) in order to provide incentives and awards to sel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2022 SORRENTO THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2022 SORRENTO THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2022 SORRENTO THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

SCLX / Scilex Holding Company / Sorrento Therapeutics, Inc. - SC 13D Activist Investment

SC 13D 1 d606606dsc13d.htm SC 13D UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Scilex Holding Company (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) Common Stock - 80880W106 (CUSIP Number) Dr. Henry Ji Chairman of the Board of Directors, President and Chief E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36150 SORRENTO THERAPEU

Bridge Loan Agreement, dated as of September 30, 2022, by and between Sorrento Therapeutics, Inc. and B. Riley Commercial Capital, LLC.

Exhibit 10.4 BRIDGE LOAN AGREEMENT Dated as of September 30, 2022 Sorrento Therapeutics, Inc., a Delaware corporation (the “Borrower”), and B. Riley Commercial Capital, LLC (the “Lender”) agree as follows: Article I AMOUNTS AND TERMS OF THE ADVANCES Section 1.01. The Advances. The Lender agrees, on the terms and conditions hereinafter set forth, to make an advance (the “Advance”) to the Borrower,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Com

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE September 29, 2022 Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Pay Off of Remaining Balance of its Senior Secured Notes ? Pre-emptive pay off of the Senior Secured Notes (the ?Notes?) eliminated the prior $28.0 million increase in the principal amount of the Notes PALO ALTO and SAN DIEGO, CA. September 29, 2022 /Newswire/ - Scilex Holding Co

Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Com

Amendment No. 1 to Agreement and Plan of Merger, dated as of September 12, 2022, by and among Vickers Vantage Corp. I, Vantage Merger Sub Inc. and Scilex Holding Company.

Exhibit 2.1 Execution Version AMENDMENT NO.1 TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this ?Amendment?), dated as of September 12, 2022, is made and entered into by and among Vickers Vantage Corp. I, a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, ?Parent?), Vantage Merger Sub Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2022 SORRENTO THERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Com

Amendment No. 1 to Agreement and Plan of Merger, dated as of September 12, 2022, by and among Vickers Vantage Corp. I, Vantage Merger Sub Inc. and Scilex Holding Company.

Exhibit 2.1 Execution Version AMENDMENT NO.1 TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this ?Amendment?), dated as of September 12, 2022, is made and entered into by and among Vickers Vantage Corp. I, a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, ?Parent?), Vantage Merger Sub Inc

Stockholder Agreement, dated as of September 12, 2022, by and among Sorrento Therapeutics, Inc. and Vickers Vantage Corp. I (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 14, 2022).

Exhibit 10.2 Execution Version STOCKHOLDER AGREEMENT THIS STOCKHOLDER AGREEMENT (this ?Agreement?), dated as of September 12 2022, is made and entered into by and among Vickers Vantage Corp. I, a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, the ?Company?), and Sorrento Therapeutics, Inc., a Delaware corporation (?Stockholde

Stockholder Agreement, dated as of September 12, 2022, by and among Sorrento Therapeutics, Inc. and Vickers Vantage Corp. I.

Exhibit 10.2 Execution Version STOCKHOLDER AGREEMENT THIS STOCKHOLDER AGREEMENT (this ?Agreement?), dated as of September 12 2022, is made and entered into by and among Vickers Vantage Corp. I, a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, the ?Company?), and Sorrento Therapeutics, Inc., a Delaware corporation (?Stockholde

Amendment No. 1 to Sponsor Support Agreement, dated as of September 12, 2022, by and among Vickers Vantage Corp. I, Scilex Holding Company and each of the Persons set forth on Schedule I attached thereto.

Exhibit 10.3 Execution Version AMENDMENT NO.1 TO SPONSOR SUPPORT AGREEMENT This Amendment to Sponsor Support Agreement (this ?Amendment?), dated as of September 12, 2022 , is made and entered into by and among, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Jeffrey Chi, Chris Ho, Pei Wei Woo, Suneel Kaji, Steve Myint, Vickers Vantage Corp I, a Cayman Islands exempted comp

Contribution and Satisfaction of Indebtedness Agreement, dated as of September 12, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Scilex Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 14, 2022).

Exhibit 10.1 Execution Version CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENT This CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENT (this ?Agreement?), entered into as of September 12, 2022 (the ?Agreement Date?), is by and among SORRENTO THERAPEUTICS, INC., a Delaware corporation (the ?Sorrento?), SCILEX HOLDING COMPANY, a direct wholly owned subsidiary of Sorrento (?Scilex?), and

Contribution and Satisfaction of Indebtedness Agreement, dated as of September 12, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Scilex Pharmaceuticals, Inc.

Exhibit 10.1 Execution Version CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENT This CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENT (this ?Agreement?), entered into as of September 12, 2022 (the ?Agreement Date?), is by and among SORRENTO THERAPEUTICS, INC., a Delaware corporation (the ?Sorrento?), SCILEX HOLDING COMPANY, a direct wholly owned subsidiary of Sorrento (?Scilex?), and

Amendment No. 1 to Sponsor Support Agreement, dated as of September 12, 2022, by and among Vickers Vantage Corp. I, Scilex Holding Company and each of the Persons set forth on Schedule I attached thereto (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 14, 2022).

Exhibit 10.3 Execution Version AMENDMENT NO.1 TO SPONSOR SUPPORT AGREEMENT This Amendment to Sponsor Support Agreement (this ?Amendment?), dated as of September 12, 2022 , is made and entered into by and among, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Jeffrey Chi, Chris Ho, Pei Wei Woo, Suneel Kaji, Steve Myint, Vickers Vantage Corp I, a Cayman Islands exempted comp

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 1, 2022 SORRENTO THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 1, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 1, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121

Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121 August 30, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, DC 20549 Attention: Sasha Parikh Daniel Gordon Re: Sorrento Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2021 Filed March 11, 2022 Form 10-Q for Fiscal Quarter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36150 SORRENTO THERAPEUTICS,

Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121

Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121 August 15, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, DC 20549 Attention: Sasha Parikh Daniel Gordon Re: Sorrento Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2021 Filed March 11, 2022 Form 10-Q for Fiscal Quarter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-36150 CUSIP Number: 83587F202 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: June 30, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Trans

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2022 SORRENTO THERAPEUTI

425 1 tm2218419d1425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdictio

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE June 14, 2022 Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba?, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US. ? Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults. ? Gout is

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE June 3, 2022 Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes PALO ALTO and SAN DIEGO, CA. June 3, 2022 /Newswire/ - Scilex Holding Company (?Scilex?), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, ?Sorrento?), a commercial biopharmaceu

Consent Under and Amendment No. 4 to Indenture, dated June 3, 2022, by and among Sorrento Therapeutics, Inc., Scilex Pharmaceuticals Inc., U.S. Bank Trust Company, National Association, as trustee and collateral agent, and the beneficial owners of the senior secured notes due 2026 and the holders of such securities listed on the signature pages thereto.

Exhibit 10.1 CONSENT UNDER AND AMENDMENT NO. 4 TO INDENTURE This CONSENT UNDER AND AMENDMENT NO. 4 TO INDENTURE is entered into as of June 2, 2022 (this ?Amendment?) by and among SCILEX PHARMACEUTICALS INC., a Delaware corporation (the ?Issuer?), SORRENTO THERAPEUTICS, INC., a Delaware corporation (the ?Parent Guarantor?), U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (as successor in interest to

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2022 SORRENTO THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commissio

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commissio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commissio

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE May 18, 2022 Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors San Diego, California. May 18, 2022 / Globe Newswire / -Sorrento Therapeutics, Inc. (Nasdaq: SRNE, ?Sorrento?), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, ann

Outside Director Compensation Policy.

Exhibit 10.2 Sorrento Therapeutics, Inc. Outside Director Compensation Policy Last Updated Effective January 1, 2022 Each director of Sorrento Therapeutics, Inc. (the ?Company?) that is not an employee of the Company (a ?Non-Employee Director?) is entitled to receive, in such director?s capacity as a non-employee director, a $82,500 annual cash retainer, with the amount being increased to $117,000

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36150 SORRENTO THERAPEUTICS

Bridge Loan Agreement, dated as of February 16, 2022, by and between Sorrento Therapeutics, Inc. and B. Riley Commercial Capital, LLC.

EX-10.1 2 srne-ex101.htm EX-10.1 Exhibit 10.1 BRIDGE LOAN AGREEMENT Dated as of February 16, 2022 Sorrento Therapeutics, Inc., a Delaware corporation (the “Borrower”), and B. Riley Commercial Capital, LLC (the “Lender”) agree as follows: ARTICLE I AMOUNTS AND TERMS OF THE ADVANCES SECTION 1.01. The Advances. The Lender agrees, on the terms and conditions hereinafter set forth, to make an advance (

Offer Letter, dated April 27, 2022, between Scilex Holding Company and Elizabeth A. Czerepak (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on April 28, 2022).

Exhibit 10.2 April 27, 2022 Elizabeth Czerepak [?***?] [?***?] Dear Elizabeth, Scilex Holding Company (?Scilex Holding? or the ?Company?) would like to offer you a position as Executive Vice President, Chief Business and Chief Financial Officer. In this position, you will report to Jaisim Shah, Chief Executive Officer. Should you accept our offer of employment, we would like your start date to be

Offer Letter, dated April 27, 2022, between Sorrento Therapeutics, Inc. and Elizabeth A. Czerepak (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on April 28, 2022).

Exhibit 10.1 April 27, 2022 Elizabeth Czerepak [?***?] [?***?] Dear Elizabeth, Sorrento Therapeutics, Inc. (?Sorrento Holding? or the ?Company?) would like to offer you a position as Executive Vice President and Chief Financial Officer. In this position, you will report to Henry Ji, Chief Executive Officer. Should you accept our offer of employment, we would like your start date to be May 18, 2022

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commiss

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE April 28, 2022 Scilex Holding Company a majority-owned subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO) SAN DIEGO, CA AND PALO ALTO, CA. April 28, 2022 /Newswire/ - Scilex Holding Company (?Scilex?), a near

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE April 4, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido? with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022 ? ZTlido 53% year-over-year preliminary unaudited gross sales in March 2022 ? Select payor accounts rep

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 4, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commissi

Innovative Leader in Non - Opioid Pain Therapeutics (March 2022)

Exhibit 99.1 Innovative Leader in Non - Opioid Pain Therapeutics (March 2022) Safe Harbor Statements Forward - Looking Statements Certain statements contained in this corporate presentation (this ?Presentation?), along with certain statements that may be ma de by management of Scilex Holding Company (together with its subsidiaries, ? Scilex ?) orally in presenting this material, are or may be cons

Form of Amended and Restated Registration Rights Agreement.

Exhibit 10.3 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of , 2022, is made and entered into by and among, (i) Scilex Holding Company, a Delaware corporation formerly known as Vickers Vantage Corp. I (the ?Company?), (ii) the equityholders designated as Sponsor Equityholders on Schedule A hereto (collective

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE March 17, 2022 SCILEX HOLDING COMPANY, A MAJORITY-OWNED SUBSIDIARY OF SORRENTO THERAPEUTICS, INC., TO BECOME PUBLICLY TRADED THROUGH A MERGER WITH VICKERS VANTAGE CORP. I ? Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140 million in expected gross proceeds be

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commiss

Sponsor Support Agreement, dated as of March 17, 2022, by and among Vickers Vantage Corp. I and each of the Persons set forth on Schedule I attached thereto.

Exhibit 10.1 EXECUTION COPY SPONSOR SUPPORT AGREEMENT This Sponsor Support Agreement (this ?Agreement?) is dated as of March 17, 2022, by and among the Persons set forth on Schedule I attached hereto (each, a ?Sponsor? and, together, the ?Sponsors?), Vickers Vantage Corp I, a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing) (?P

# # #

Exhibit 99.2 FOR IMMEDIATE RELEASE March 18, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA?) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity ? SP-102 (SEMDEXA?), with 401 patients enrolled in the C.L.E.A.R.

Company Stockholder Support Agreement, dated as of March 17, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Vickers Vantage Corp. I.

Exhibit 10.2 EXECUTION VERSION COMPANY STOCKHOLDER SUPPORT AGREEMENT This COMPANY STOCKHOLDER SUPPORT AGREEMENT, dated as of March 17, 2022 (this ?Stockholder Support Agreement?), is entered into by and among Sorrento Therapeutics, Inc. (?Stockholder?), Scilex Holding Company, a Delaware corporation (the ?Company?) and Vickers Vantage Corp. I, a Cayman Islands exempted company (?Parent?). Capitali

# # #

Exhibit 99.2 FOR IMMEDIATE RELEASE March 18, 2022 Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA?) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity ? SP-102 (SEMDEXA?), with 401 patients enrolled in the C.L.E.A.R.

Sponsor Support Agreement, dated as of March 17, 2022, by and among Vickers Vantage Corp. I and each of the Persons set forth on Schedule I attached thereto.

Exhibit 10.1 EXECUTION COPY SPONSOR SUPPORT AGREEMENT This Sponsor Support Agreement (this ?Agreement?) is dated as of March 17, 2022, by and among the Persons set forth on Schedule I attached hereto (each, a ?Sponsor? and, together, the ?Sponsors?), Vickers Vantage Corp I, a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing) (?P

Form of Amended and Restated Registration Rights Agreement.

Exhibit 10.3 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of , 2022, is made and entered into by and among, (i) Scilex Holding Company, a Delaware corporation formerly known as Vickers Vantage Corp. I (the ?Company?), (ii) the equityholders designated as Sponsor Equityholders on Schedule A hereto (collective

Agreement and Plan of Merger, dated as of March 17, 2022, by and among Vickers Vantage Corp. I, Vantage Merger Sub Inc. and Scilex Holding Company.

Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of March 17, 2022 by and among Vickers Vantage Corp. I, Vantage Merger Sub Inc., and Scilex Holding Company TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 ARTICLE II DOMESTICATION 15 2.1 Domestication 15 ARTICLE III MERGER 16 3.1 Merger 16 3.2 Closing; Effective Time 16 3.3 Directors and Officers 16 3.4 Effect of the Merger 16 3.5

Agreement and Plan of Merger, dated as of March 17, 2022, by and among Vickers Vantage Corp. I, Vantage Merger Sub Inc. and Scilex Holding Company.

Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of March 17, 2022 by and among Vickers Vantage Corp. I, Vantage Merger Sub Inc., and Scilex Holding Company TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 ARTICLE II DOMESTICATION 15 2.1 Domestication 15 ARTICLE III MERGER 16 3.1 Merger 16 3.2 Closing; Effective Time 16 3.3 Directors and Officers 16 3.4 Effect of the Merger 16 3.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2022 SORRENTO THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commiss

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE March 17, 2022 SCILEX HOLDING COMPANY, A MAJORITY-OWNED SUBSIDIARY OF SORRENTO THERAPEUTICS, INC., TO BECOME PUBLICLY TRADED THROUGH A MERGER WITH VICKERS VANTAGE CORP. I ? Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140 million in expected gross proceeds be

Company Sponsor Support Agreement, dated as of March 17, 2022, by and among the Registrant and Vickers Vantage Corp. I (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on March 18, 2022).

Exhibit 10.2 EXECUTION VERSION COMPANY STOCKHOLDER SUPPORT AGREEMENT This COMPANY STOCKHOLDER SUPPORT AGREEMENT, dated as of March 17, 2022 (this ?Stockholder Support Agreement?), is entered into by and among Sorrento Therapeutics, Inc. (?Stockholder?), Scilex Holding Company, a Delaware corporation (the ?Company?) and Vickers Vantage Corp. I, a Cayman Islands exempted company (?Parent?). Capitali

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 18, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36150 SORRENTO THERAPEUTICS, INC.

Exhibit 4.19

Exhibit 4.19 Description of Securities of Sorrento Therapeutics, Inc. The authorized capital stock of Sorrento Therapeutics, Inc., a Delaware corporation (the ?Company?), consists of: ? 750,000,000 shares of common stock, $0.0001 par value per share (?Common Stock?); and ? 100,000,000 shares of preferred stock, $0.0001 par value per share (?Preferred Stock?). Common Stock Except as otherwise expre

List of Subsidiaries

EX-21.1 3 srne-ex211.htm EX-21.1 Exhibit 21.1 Subsidiaries of Sorrento Therapeutics, Inc. Name State or Jurisdiction of Incorporation or Organization Concortis Biosystems, Corp. Delaware Ark Animal Health, Inc. Delaware TNK Therapeutics, Inc. Delaware BioServ Corporation Delaware Adnab, Inc. Delaware ACEA Therapeutics, Inc. Cayman Islands Scilex Holding Company Delaware Semnur Pharmaceuticals, Inc

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 3, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commissi

Calculation of Filing Fee Table (Form Type) Sorrento Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

EX-FILING FEES 2 tm228298d2ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table 424b7 (Form Type) Sorrento Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price(2)

1,281,662 Shares Sorrento Therapeutics, Inc. Common Stock

Filed pursuant to Rule 424(b)(7) Registration No. 333-261888 PROSPECTUS SUPPLEMENT (to prospectus dated December 23, 2021) 1,281,662 Shares Sorrento Therapeutics, Inc. Common Stock This prospectus supplement relates to the resale by the selling stockholders listed in the section of this prospectus entitled ?Selling Stockholders,? or the Selling Stockholders, of up to 1,281,662 shares, or the Share

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-36150 CUSIP Number: 83587F202 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? T

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

# # #

Exhibit 99.1 IMMEDIATE RELEASE February 17, 2022 SORRENTO ANNOUNCES THAT IT HAS ACQUIRED A MAJORITY OWNERSHIP IN DIAGNOSTIC MANUFACTURER ZHENGZHOU FORTUNE BIOSCIENCE IN RESPONSE TO INCREASING WORLDWIDE DEMAND FOR COVISTIX? ? COVISTIX is a highly sensitive and rapid antigen detection test for SARS-CoV-2 and its major variants of concern (VOCs), including the Omicron variant. ? COVISTIX has an enhan

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

SRNE / Sorrento Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Sorrento Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 83587F202 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b

# # #

Exhibit 99.1 IMMEDIATE RELEASE February 1, 2022 SORRENTO COMPLETES ACQUISITION OF VIREX HEALTH, WILL COMMERCIALIZE NEXT-GENERATION AT-HOME DIAGNOSTIC TESTING THAT RIVALS PCR-LEVEL SENSITIVITY FOR DAILY COVID-19 TESTS AND EARLY CANCER DIAGNOSIS ? Virex Health, Inc. is a Boston, Massachusetts company that has developed a powerful, broadly applicable at-home diagnostic platform (?Virex Technology?).

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commi

Disclaimer Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc . (the “Company”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in pre

EX-99.1 2 tm224146d1ex99-1.htm EXHIBIT 99.1 Sorrento Potent Omicron Neutralizing Antibody (nAb) STI - 9167 IV STI - 9199 IN Exhibit 99.1 Disclaimer Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc . (the “Company”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 21, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commi

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 20, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commi

# # #

EX-99.1 2 tm223966d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE January 20, 2022 SORRENTO THERAPEUTICS announces COVISHIELD (STI-9167), a BROAD-SPECTRUM NEUTRALIZING ANTIBODY, POTENTLY NEUTRALIZES OMICRON AND OMICRON (+R346K) VARIANTS of sars-cov-2 · COVISHIELD (STI-9167) neutralizing antibody (nAb) was discovered by scientists from the Icahn School of Medicine at Mount Sinai (“Icah

Agreement and Plan of Merger, dated January 14, 2022, by and among Sorrento Therapeutics, Inc., VH Merger Sub I, Inc., VH Merger Sub II, LLC, Virex Health, Inc. and Fortis Advisors LLC, as representative of the stockholders of Virex Health, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 1, 2022).

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among SORRENTO THERAPEUTICS, INC., as Parent VH MERGER SUB I, INC., as Merger Sub VH MERGER SUB II, LLC, as Merger LLC Virex Health Inc. as the Company and FORTIS ADVISORS LLC as the Stockholders? Representative Dated as of January 14, 2022 1 Article I DEFINITIONS 6 Section 1.1 Certain Defined Terms 6 Section 1.2 Table of Definitions 22 Article II THE MERGE

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 14, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2022 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commis

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE January 7, 2022 Sorrento Therapeutics Announces the Unexpected Death of its Chief Financial Officer SAN DIEGO, January 7th, 2022 (GLOBE NEWSWIRE) - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the unexpected passing of Mr. Najjam Asghar, Chief Financial Officer and Senior Vice President. Mr. Asghar died of apparent natural causes on Janu

As filed with the Securities and Exchange Commission on December 23, 2021

S-3ASR 1 tm2136221d1s3asr.htm S-3ASR As filed with the Securities and Exchange Commission on December 23, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor

Amendment No. 1 to Amended and Restated Sales Agreement, dated as of December 23, 2021, by and among Sorrento Therapeutics, Inc., Cantor Fitzgerald & Co., B. Riley Securities, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed with the SEC on December 23, 2021).

Exhibit 1.2 AMENDMENT NO. 1 TO AMENDED AND RESTATED SALES AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED SALES AGREEMENT (this ?Amendment?) dated as of December 23, 2021, is made by and among Sorrento Therapeutics, Inc. (the ?Company?), on the one hand, and Cantor Fitzgerald & Co., B. Riley Securities, Inc. and H.C. Wainwright & Co., LLC (each individually, a ?Sales Agent? and together, th

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 23, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

Amendment No. 1 to Amended and Restated Sales Agreement, dated December 23, 2021, by and among Sorrento Therapeutics, Inc., Cantor Fitzgerald & Co., B. Riley Securities, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.3 to the Registrant’s Registration Statement on Form S-3ASR, filed with the SEC on December 23, 2021)

Exhibit 1.3 AMENDMENT NO. 1 TO AMENDED AND RESTATED SALES AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED SALES AGREEMENT (this ?Amendment?) dated as of December 23, 2021, is made by and among Sorrento Therapeutics, Inc. (the ?Company?), on the one hand, and Cantor Fitzgerald & Co., B. Riley Securities, Inc. and H.C. Wainwright & Co., LLC (each individually, a ?Sales Agent? and together, th

Form of Indenture (incorporated by reference to Exhibit 4.21 to the Registrant’s Registration Statement on Form S-3ASR, filed with the SEC on December 23, 2021)

EX-4.21 3 tm2136221d1ex4-21.htm EXHIBIT 4.21 Exhibit 4.21 Sorrento Therapeutics, Inc. INDENTURE Dated as of [ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 5 Sectio

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

THIS DOCUMENT CONTAINS PROPRIETARY INFORMATION THAT IS THE PROPERTY OF THE COMPANY . NEITHER THIS DOCUMENT, NOR THE PROPRIETARY INFORMATION CONTAINED HEREIN, SHALL BE PUBLISHED, REPRODUCED, COPIED, DISCLOSED OR USED FOR ANY OTHER PURPOSE, OTHER THAN

C C on f on f i i den t de n t i i a l a l : : F F o r or I I n n t t e e r r na l nal S S C C I I L E L E X X P P h ha r ar m m a c a c eu t eu t i i c c a l a l s s U U s e se O n On l l y y 1 1 Scilex Holding Company Innovative Leader in Non - Opioid Pain Therapeutics December 2021 Exhibit 99.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commi

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE December 9, 2021 Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA?) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy ? Scilex Holding Company, a commercial-sta

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE December 6, 2021 Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (?SPAC?) Enter into Letter of Intent for Proposed Business Combination ? Scilex Holding Company (Scilex) a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), and Vickers Vantage Corp I (Nasdaq: VCKA) announce signing of a letter of in

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 6, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commi

Common Stock

424B5 1 tm2134539d2424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-237142 Supplement No. 1 dated December 3, 2021 To Prospectus Supplement dated December 4, 2020 (to Prospectus dated March 20, 2020) $450,000,000 Common Stock This supplement, or this Supplement, supplements certain information contained in the prospectus supplement dated December 4, 2020, or the Prospectus Sup

Amended and Restated Sales Agreement, dated December 3, 2021, by and among Sorrento Therapeutics, Inc., Cantor Fitzgerald & Co., B. Riley Securities, Inc., H.C. Wainwright & Co., LLC and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 1.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on December 3, 2021)

Exhibit 1.1 Sorrento Therapeutics, Inc. COMMON STOCK AMENDED AND RESTATED SALES AGREEMENT December 3, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, New York 10171 H.C. Wainwright & Co., LLC 430 Park Avenue, 4th Floor New York, NY 10022 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies

# # #

Exhibit 99.2 FOR IMMEDIATE RELEASE November 29, 2021 SORRENTO publishes an abivertinib teaser entitled ?Abivertinib ? a franchise oral therapeutic for cancer, covid-19 and autoimmune diseases? SAN DIEGO, November 29, 2021 (GLOBE NEWSWIRE) - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the publication of a Teaser titled ?Abivertinib ? a Franchise Oral Therapeutic for Cance

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

Abivertinib – A Franchise Oral Therapeutic

Exhibit 99.1 Abivertinib ? A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases EXECUTIVE SUMMARY Abivertinib ? A Broad Pipeline for Cancer, COVID-19 and Autoimmune Diseases ($61B Market) About Abivertinib: ? Abivertinib is a novel dual target, small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) an

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Comm

# # #

EX-99.1 2 tm2132211d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE November 7, 2021 SORRENTO AWARDED CALIFORNIA COMPETES TAX CREDIT SAN DIEGO, November 7, 2021 (GLOBE NEWSWIRE) - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the California Competes Tax Credit Committee has approved the California Competes Tax Credit Allocation Agreement (the “Agreement”)

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commi

Sorrento Gateway Lease, dated September 1, 2021, by and between Sorrento Therapeutics, Inc. and HCP Life Science REIT, Inc. (4930 Directors Place) (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2021).

EX-10.1 2 srne-ex101.htm EX-10.1 Exhibit 10.1 SORRENTO GATEWAY LEASE This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation (“Landlord”), and SORRENTO THERAPEUTICS, INC., a Delaware corporation (“Tenant”). SUMMARY OF BASIC LEASE INFORMATION TER

First Amendment to Office Lease, dated October 10, 2020, by and between Sorrento Therapeutics, Inc. and HCP Life Science Estates, Inc. (4939 Directors Place) (incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2021).

Exhibit 10.4 FIRST AMENDMENT TO OFFICE LEASE This FIRST AMENDMENT TO OFFICE LEASE ("First Amendment") is made and entered into as of October 10, 2020, by and between HCP LIFE SCIENCE ESTATES, INC., a Delaware corporation ("Landlord"), and SORRENTO THERAPEUTICS, INC., a Delaware corporation ("Tenant"). R E C I T A L S: A. Landlord and Tenant are parties to the Lease dated November 13, 2018 (the "Le

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36150 SORRENTO THERAPEU

Second Amendment to Office Lease, dated September 1, 2021, by and between Sorrento Therapeutics, Inc. and HCP Life Science REIT, Inc. (4955 Directors Place) (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2021).

Exhibit 10.3 SECOND AMENDMENT TO OFFICE LEASE This SECOND AMENDMENT TO OFFICE LEASE ("Second Amendment") is made and entered into as of September 1, 2021, by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord"), and SORRENTO THERAPEUTICS, INC., a Delaware corporation ("Tenant"). R E C I T A L S : A. Landlord and Tenant are parties to the Lease dated September 8, 2016 (the "

First Amendment to Office Lease, dated September 14, 2021, by and between Sorrento Therapeutics, Inc. and HCP Life Science REIT, Inc. (4930 Directors Place) (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2021).

Exhibit 10.2 FIRST AMENDMENT TO OFFICE LEASE This FIRST AMENDMENT TO OFFICE LEASE ("First Amendment") is made and entered into as of September 14, 2021, by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord"), and SORRENTO THERAPEUTICS, INC., a Delaware corporation ("Tenant"). R E C I T A L S : A. Landlord and Tenant are parties to the Lease dated September 1, 2021 (the "Le

Second Amendment to Office Lease, dated September 1, 2021, by and between Sorrento Therapeutics, Inc. and HCP Life Science REIT, Inc. (4939 Directors Place) (incorporated by reference to Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2021).

Exhibit 10.5 SECOND AMENDMENT TO OFFICE LEASE This SECOND AMENDMENT TO OFFICE LEASE ("Second Amendment") is made and entered into as of September 1, 2021, by and between HCP LIFE SCIENCE REIT, INC., a Maryland corporation ("Landlord"), and SORRENTO THERAPEUTICS, INC., a Delaware corporation ("Tenant"). R E C I T A L S : A. Landlord (incorrectly listed in the Lease as HCP LIFE SCIENCE ESTATES, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

PRE 14A 1 srne-pre14a20211115.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 13, 2021 SORRENTO THERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 13, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Com

Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc . (the “Company” or “Sorrento”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in

Saving Life TM Medicine September 20 21 NASDAQ : SRNE ? 2021 Sorrento Therapeutics, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commis

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE August 11, 2021 Sorrento and DYADIC Announce Binding Term Sheet to License Dyadic?s LEAD COVID-19 VAccine Candidate ?DYAI-100? AND C1 Technology for protein-based coronavirus vaccineS and therapeutics ? Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to u

2 © 2021 Sorrento Therapeutics, Inc. All Rights Reserved HQ in San Diego, CA ~ 700 Employees worldwide ~100 Employees with PhDs & MDs >5 00,000 SF Research and cGMP Manufacturing Facilities 1 FDA Approved Drug ZTlido ® (lidocaine topical system)1.8%

SARS - CoV - 2 Vaccine Countermeasures August 20 21 NASDAQ : SRNE ? 2021 Sorrento Therapeutics, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commiss

# # #

Exhibit 99.2 FOR IMMEDIATE RELEASE August 9, 2021 Sorrento unveils overview oF its multivalent mRNA covid-19 vaccine development program SAN DIEGO, August 9, 2021 (GLOBE NEWSWIRE) - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, announced today the availability of a prese

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36150 SORRENTO THERAPEUTICS,

CELU / Celularity Inc. Class A / Sorrento Therapeutics, Inc. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CELULARITY INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 151190105 (CUSIP Number) July 16, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

Sorrento Therapeutics, Inc. 5,519,469 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257412 PROSPECTUS Sorrento Therapeutics, Inc. 5,519,469 Shares of Common Stock This prospectus relates to the resale by the investors listed in the section of this prospectus entitled “Selling Stockholders,” or the Selling Stockholders, of up to 5,519,469 shares, or the Shares, of our common stock, par value $0.0001 per share, or Common Stock.

Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121

Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121 July 13, 2021 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-0406 Re: Sorrento Therapeutics, Inc. Registration Statement on Form S-3, Filed on June 25, 2021 File No. 333-257412 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Sorrento Therapeuti

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commissio

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commiss

As filed with the Securities and Exchange Commission on June 25, 2021

S-3 1 srne-s3.htm S-3 As filed with the Securities and Exchange Commission on June 25, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organizati

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE June 2, 2021 Sorrento completes acquisition of acea therapeutics, creating a major oncology franchise ? among multiple clinical- and preclinical-stage NCE (new chemical entity) compounds acquired, abivertinib is an anchoring late-stage drug product with positive clinical trial results in both Non-small cell lung cancer (NSCLC) and b-cell lymphoma: o Abivertinib i

Earn-Out Agreement, dated June 1, 2021, by and between Sorrento Therapeutics, Inc. and Fortis Advisors LLC (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 4, 2021).

Exhibit 10.1 ***Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets (?[...***...]?) in this exhibit. *** EARN-OUT AGREEMENT THIS EARN-OUT AGREEMENT, dated as of June 1, 2021 (this ?Agreement?), is entered into by a

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commissio

Contract, dated August 15, 2018, by and between Hangzhou ACEA Pharmaceutical Research Co., Ltd. and ACEA Bio (Hangzhou) Co., Ltd. (translated into English from its original text in Chinese) (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 4, 2021).

Exhibit 10.2 Contract Borrower (Party A): Hangzhou ACEA Pharmaceutical Research Co., Ltd. Lender (Party B): ACEA Bio (Hangzhou) Co., Ltd. Party A and Party B, intending to be legally bound, hereby enter into this Contract through full negotiation on the basis of mutual consensus previously achieved with respect to the loan amounts shown below arising out of Party B?s payment of funds on Party A?s

Loan Agreement, dated January 6, 2018, by and between Zhejiang ACEA Pharmaceutical Co., Ltd. and ACEA Bio (Hangzhou) Co., Ltd. (translated into English from its original text in Chinese) (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 4, 2021).

Exhibit 10.3 Loan Agreement Borrower: Zhejiang ACEA Pharmaceutical Co., Ltd. Legal Representative: XU XIAO Legal Address: No.11 North Huayin Road, Kecheng District, Quzhou City, Zhejiang Province Registration No.: 91330800MA28F0XMXR Tel.: 0570-8872301 Lender: ACEA Bio (Hangzhou) Co., Ltd. Legal Representative: Wang Xiaobo Legal Address: Building 5, No.2 Xiyuanwu Road, Xihu District, Hangzhou City,

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2021 SORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36150 33-0344842 (State or Other Jurisdiction of Incorporation) (Commissio

# # #

Exhibit 99.1 FOR IMMEDIATE RELEASE June 2, 2021 SORRENTO ANNOUNCES ADDITION OF COVI-STIX? (COVID-19 VIRUS RAPID ANTIGEN DETECTION TEST) TO THE OFFICIAL MEXICAN GOVERNMENT LIST OF EMERGENCY USE APPROVED POINT OF CARE RAPID ANTIGEN TESTS ? COVI-STIX has been added to the official government list of point of care rapid antigen tests useful for the detection of SARS-CoV-2 in Mexico (https://www.gob.mx

Sorrento Therapeutics, Inc. 616,655 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-256304 PROSPECTUS Sorrento Therapeutics, Inc. 616,655 Shares of Common Stock This prospectus relates to the resale by the investor listed in the section of this prospectus entitled ?Selling Stockholder,? or the Selling Stockholder, of up to 616,655 shares, or the Shares, of our common stock, par value $0.0001 per share, or Common Stock. Pursuan

Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121

Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121 May 27, 2021 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-0406 Re: Sorrento Therapeutics, Inc. Registration Statement on Form S-3, Filed on May 19, 2021 File No. 333-256304 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Sorrento Therapeutics

As filed with the Securities and Exchange Commission on May 19, 2021

As filed with the Securities and Exchange Commission on May 19, 2021 Registration No.

Sorrento Therapeutics, Inc. 2021 Cash-Settled Stock Appreciation Plan (incorporated by reference to Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on May 5, 2021).

Exhibit 10.5 SORRENTO THERAPEUTICS, INC. 2021 CASH-SETTLED STOCK APPRECIATION RIGHTS PLAN PLAN DOCUMENT 1.Establishment, Purpose, and Types of Awards Sorrento Therapeutics, Inc. (the ?Company?) hereby establishes this equity-based cash incentive compensation plan to be known as the ?Sorrento Therapeutics, Inc. 2021 Cash-Settled Stock Appreciation Rights Plan? (hereinafter referred to as the ?Plan?

Exclusive License Agreement, dated as of March 4, 2021, by and between Sorrento Therapeutics, Inc. and the Icahn School of Medicine at Mount Sinai (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on May 5, 2021).

Exhibit 10.2 ***Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets (?[...***...]?) in this exhibit. *** EXCLUSIVE LICENSE AGREEMENT between Sorrento Therapeutics, Inc. and Icahn School of Medicine at Mount Sinai T

Amendment to Binding Term Sheet, dated as of April 20, 2021, by and between Sorrento Therapeutics, Inc. and ANP Technologies, Inc.

Exhibit 10.4 Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, CA 92121 April 20, 2021 ANP Technologies, Inc. 824 Interchange Boulevard Newark, Delaware 19711 Attn: Ray Yin Dear Ray: Reference is made to that certain Term Sheet, dated February 24, 2021 (the ?Term Sheet?), between Sorrento Therapeutics, Inc. and ANP Technologies, Inc. The Term Sheet is hereby amended to extend the ?Stands

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36150 SORRENTO THERAPEUTICS

Sorrento Therapeutics, Inc. Stock Appreciation Rights Award Agreement (incorporated by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on May 5, 2021).

Exhibit 10.6 SORRENTO THERAPEUTICS, INC. 2021 CASH-SETTLED STOCK APPRECIATION RIGHTS PLAN Stock Appreciation Rights Award Agreement Award No. You (the ?Participant?) are hereby awarded the following stock appreciation rights (the ?SARs?) with respect to Shares of Sorrento Therapeutics, Inc. (the ?Company?), subject to the terms and conditions set forth in this Stock Appreciation Rights Award Agree

Binding Term Sheet, dated as of February 24, 2021, by and between Sorrento Therapeutics, Inc. and ANP Technologies, Inc.

Exhibit 10.1 TERM SHEET FOR ANP TECHNOLOGIES, INC. ACQUISITION February 24, 2021 A.Transaction: Sorrento Therapeutics, Inc. (?Sorrento?) will acquire 100% of the issued and outstanding equity of ANP Technologies, Inc. (?ANP?) and all of its subsidiaries by means of a reverse triangular merger in which a newly-formed subsidiary of Sorrento will merge with and into ANP (the ?Transaction?). In order

Sorrento Therapeutics, Inc. 851,305 Shares of Common Stock

424B3 1 srne-424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-255165 PROSPECTUS Sorrento Therapeutics, Inc. 851,305 Shares of Common Stock This prospectus relates to the resale by the investor listed in the section of this prospectus entitled “Selling Stockholders,” or the Selling Stockholder, of up to 851,305 shares, or the Shares, of our common stock, par value $0.0001 per s

Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121

Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, California 92121 April 14, 2021 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-0406 Re: Sorrento Therapeutics, Inc. Registration Statement on Form S-3, Filed on April 9, 2021 File No. 333-255165 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Sorrento Therapeut

Registration Rights Agreement, dated as of March 4, 2021, by and between Sorrento Therapeutics, Inc. and the Icahn School of Medicine at Mount Sinai (incorporated by reference to Exhibit 4.19 to the Registrant’s Registration Statement on Form S-3 filed with the SEC on April 9, 2021).

Exhibit 4.19 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made as of March 4, 2021, by and between Sorrento Therapeutics, Inc., a Delaware corporation (the ?Company?), and the Icahn School of Medicine at Mount Sinai (the ?Purchaser?). The Company and the Purchaser are entering into this Agreement contemporaneously with and in respect of the Stock Purchase

- S-3

As filed with the Securities and Exchange Commission on April 9, 2021 Registration No.

Stock Purchase Agreement, dated as of March 4, 2021, by and between Sorrento Therapeutics, Inc. and the Icahn School of Medicine at Mount Sinai.

Exhibit 4.18 SORRENTO THERAPEUTICS, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this ?Agreement?) is made as of March 4, 2021 (the ?Effective Date?), by and between Sorrento Therapeutics, Inc., a Delaware corporation (the ?Company?), and the Icahn School of Medicine at Mount Sinai (the ?Purchaser?). AGREEMENT In consideration of the mutual covenants contained in this Agreement, an